REQUIRED IMMUNIZATIONS Sample Clauses

REQUIRED IMMUNIZATIONS a) The North Dakota State Board of Higher Education policy, Section 506.1, requires students to provide proof of two MMR immunizations (Measles, Mumps and Rubella) before being accepted into North Dakota colleges. All newly admitted students ages 21 and younger must provide documentation of vaccination against meningococcal disease given after the age of
View SourceView Similar (4)
REQUIRED IMMUNIZATIONS. The North Dakota State Board of Higher Education policy, Section 506.1, requires students to provide proof of two MMR immunizations (Measles, Mumps and Rubella) before being accepted into North Dakota colleges. All newly admitted students ages 21 and younger must provide documentation of vaccination against meningococcal disease given after the age of 16. TB testing is required of International students from countries classified by U.S. health officials as “high burden countries for tuberculosis.” For more information on these requirements and possible exemptions, visit: ▇▇▇.▇▇▇▇▇.▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇▇.
View SourceView Similar (4)
REQUIRED IMMUNIZATIONS. The following requirements apply to this Contract only if a box or boxes are checked below. Prior to contract signing and throughout the term of this Contract, including any renewals, the Contractor’s employees performing services under this Contract must be immunized or prove immunity to specific diseases through serology where noted, and must provide a negative TB test, if indicated below. If no boxes are checked, none of these requirements apply to this Contract. Measles, Mumps and Rubella (MMR) 2 doses OR serology Tetanus, Diphtheria, and Pertussis (Tdap) 1 dose Varicella (chicken pox) 2 doses OR serology Influenza (Due by Nov. 1 each year) 1 dose Covid-19 (Due by Nov. 1 each year) 1 dose Negative TB skin test (within past year) Other: _____________________________________________________________ Proof: Contractor shall provide proof of each employee’s immunization, serology, and negative TB skin test (when checked above) to PHMDC no later than the Contract start date or as otherwise agreed by the parties. Contractor shall ensure its employees stay up to date on all of these requirements while this Contract is in place, and during any renewals. Changes during Contract Term: PHMDC reserves the right to update or modify these requirements, including adding more required immunizations, if PHMDC’s employee health policies are updated, or in response to emerging public health situations or pandemics. PHMDC will notify Contractor of such changes in writing using the notice procedures in section 14 and will provide a date for compliance. If requested by the Contractor, the parties will work together to develop a reasonable plan for Contractor compliance with any such changes. Contractor shall ensure its employees performing services under this Contract comply by the date in the notice or as agreed by the parties in writing.
View Source
REQUIRED IMMUNIZATIONS. Upon entrance to NCP’s program, children will need to have updated immunizations. No exception is made per Senate Bill 277. NCP is happy to assist with questions regarding specific shots needed and can provide information from the Santa ▇▇▇▇▇ Health department (see ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/▇▇▇/▇▇▇▇▇).
View Source
REQUIRED IMMUNIZATIONS. In the event that a member of the department is exposed to a communicable disease in the line of duty and a physician recommends that a certain shot or shots be given to the employee, the City will pay for the cost of such shot or shots. Where the physician also recommends that members of the employee's family living at home be given the shot or shots, the City will pay for the cost of such shot or shots.
View Source
REQUIRED IMMUNIZATIONS. See section 27.
View Source

Related to REQUIRED IMMUNIZATIONS

  • Immunizations (except for those preventive immunizations for routine use in children, adolescents, and adults that have in effect a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention);

  • Immunization The following immunizations are recommended by the BSA. Tetanus immunization is required and must have been received within the last 10 years. If you had the disease, check the disease column and list the date. If immunized, check yes and provide the year received.

  • COVID-19 Vaccinations Contractor understands, acknowledges, and agrees that, pursuant to Article II of the General Appropriations Act, none of the General Revenue Funds appropriated to the Department of State Health Services (DSHS) may be used for the purpose of promoting or advertising COVID-19 vaccinations in the 2024-25 biennium. It is also the intent of the legislature that to the extent allowed by federal law, any federal funds allocated to DSHS shall be expended for activities other than promoting or advertising COVID-19 vaccinations. Contractor represents and warrants that it is not ineligible, nor will it be ineligible during the term of this Contract, to receive appropriated funding pursuant to Article II.

  • Adverse Events Subsequent to the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange, the NASDAQ National Market or the NASDAQ Global Market, (ii) a general moratorium on commercial banking activities in the People’s Republic of China or New York, (iii) the outbreak or escalation of hostilities involving the United States or the People’s Republic of China or the declaration by the United States or the People’s Republic of China of a national emergency or war if the effect of any such event specified in this clause (iii) in your reasonable judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus, or (iv) such a material adverse change in general economic, political, financial or international conditions affecting financial markets in the United States or the People’s Republic of China having a material adverse impact on trading prices of securities in general, as, in your reasonable judgment, makes it impracticable or inadvisable to proceed with the public offering of the Shares or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus.

  • Regulatory Materials (a) On a Program-by-Program basis, commencing on the Effective Date until the Regulatory Transfer Date, Prothena shall have the right, in consultation with Celgene, to prepare, file and maintain all Regulatory Materials (including any Regulatory Approvals) necessary for the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program (collectively, the “Program Regulatory Materials”), and to interact with Regulatory Authorities in connection with the Development and Manufacture of any Collaboration Candidates and Collaboration Products for such Program. Prothena will provide Celgene with a reasonable opportunity to comment substantively on all material Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Celgene, including with respect to filing strategy. In addition, Prothena will allow Celgene or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. (b) If Celgene exercises its Phase 1 Portion Participation Right for a given Program, then immediately after such exercise, Prothena shall initiate the transfer of all Program Regulatory Materials, including for clarity any IND for the relevant Collaboration Candidates and/or Collaboration Products that are the subject of such Program to Celgene. The date on which such Program Regulatory Materials are transferred to Celgene shall be the “Regulatory Transfer Date” for such Program. Thereafter, Celgene shall have the right, in consultation with Prothena, to prepare, file, and maintain such Program Regulatory Materials, and to interact with Regulatory Authorities in connection with the Development and, as applicable, Manufacture of such Collaboration Candidates and Collaboration Products for such Program in accordance with the terms and conditions of Section 2.5. Additionally, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will provide Prothena with a reasonable opportunity to comment substantively on all material Program Regulatory Materials prior to filing or taking material action, and will reasonably and in good faith consider any comments and actions recommended by Prothena, including with respect to filing strategy. In addition, with respect to any Phase 1 Clinical Trial conducted by Celgene pursuant to Section 2.5, Celgene will allow Prothena or its representative to attend any and all meetings with Regulatory Authorities to the extent such attendance is not prohibited or limited by such Regulatory Authority. For clarity, if the Regulatory Transfer Date does not occur prior to the expiration of the Option Term for such Program, Section 2.6.1(a) (and not this Section 2.6.1(b)) shall apply.